[en] The influence of some peptidase inhibitors on oedema and plasma extravasation induced by bradykinin and carrageenan in rat paw was evaluate. Bradykinin-induced oedema in normal rats was increased by o-phenanthroline (3.10(-2) M), by captopril (10(-6) M to 10(-4) M), by lisinopril (10(-6) M to 10(-4), or by lisinopril (10(-5) M) in combination with apstatin (8.10(-5) M or 1.4 10(-4) M). It was not modified by phosphoramidon (10(-6) M to 10(-5) M) and by diprotin A (10(-3) M). It was increased by mergepta at high concentrations (2.10(-4) M). Mergepta did not increase the potentiating effect of captopril. Carrageenan-oedema in normal rats was increased by captopril (10(-5) M), lisinopril (10(-5) M) and apstatin (1.4 10(-4) M. It was not modified by mergepta (10(-4) M), phosphoramidon (10 (-5) M) and diprotin A (109-3) M). Des-Arg1-bradykinin and Des-Arg9-bradykinin have low oedema-promoting effects. Captopril (10(-5) M) increased the effects of bradykinin but not those of carrageenan in kininogen-deficit Brown Norway rats. Angiotensin-converting enzyme and aminopeptidase P appear to be main kinin-inactivating enzymes in rat paws. Carboxypeptidase N, neutral endopeptidase 24.11 and dipeptidyl(amino)peptidase IV do not play a significant role in this inactivation.
Disciplines :
Pharmacie, pharmacologie & toxicologie
Auteur, co-auteur :
Damas, Jacques ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques
Liégeois, Jean-François ; Université de Liège - ULiège > Département de pharmacie > Chimie pharmaceutique
Simmons, W. H.
Langue du document :
Anglais
Titre :
Potentiation of the Pro-Inflammatory Effects of Bradykinin by Inhibition of Angiotensin-Converting Enzyme and Aminopeptidase P in Rat Paws
Adam A, Damas J, Vranckx R (1986) Trypsin-like activity in salivary glands of the rat. Br J Pharmacol 89:589P
Barabé J, Huberdeau D (1991) A micromethod for the determination of the activities of kininases in rat plasma. Biochem Pharmacol 41:821-827
Barlas A, Gao X, Greenbaum LM (1987) Isolation of a thiol-activated T-kininogenase from the rat submandibular gland. FEBS Lett 218:266-270
Boura ALA, Svolmanis AP (1984) Converting enzyme inhibition in the rat by captopril is accompanied by potentiation of carrageenin-induced inflammation. Br J Pharmacol 82:3-8
Campos MM, Calixto JB (1995) Involvement of B1 and B2 receptors in bradykinin-induced rat paw oedema. Br J Pharmacol 114:1005-1013
Damas J, Adam A (1980) Congenital deficiency in plasma kallikrein and kininogens in the Brown Norway rat. Experentia 36:586-587
Damas J, Adam A (1985) The relationship between kininogens and kallikreins in Brown Norway deficient rat plasma. Mol Physiol 8:307-316
Damas J, Remacle-Volon G (1992) Influence of a long-acting bradykinin antagonist, HOE 140, on some acute inflammatory reactions in the rat. Eur J Pharmacol 211:81-86
Damas J, Remacle-Volon G, Adam A (1984) Inflammation in the rat paw due to urate crystals. Involvement of the kinin system, Naunyn-Schmiedeberg's Arch Pharmacol 325:76-79
Damas J, Remacle-Volon G, Deflandre E (1986) Further studies of the mechanism of counter irritation by turpentine. Naunyn-Schmiedeberg's Arch Pharmacol 332:196-200
Damas J, Bourdon V, Remacle-Volon G, Adam A (1990) Kinins and peritoneal exudates induced by carrageenin and zymosan in rats. Br J Pharmacol 101:418-422
Décarie A, Drapeau G, Closset J, Couture R, Adam A (1994) Development of digoxin-labeled peptide: Application to chemiluminoenzyme immunoassay of bradykinin in inflamed tissues. Peptides 15:511-518
Diniz CR, Carvalho IV (1963) A micromethod for determination of bradykininogen under several conditions. Ann N Y Acad Sci 104:77-86
Dragovic T, Minshall R, Jackman HL, Wang LX, Erdös EG (1996) Kininase II-Type enzymes. Their putative role in muscle energy metabolism. Diabetes 45:S34-S37
Erdös EG, Skidgel RA (1989) Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 3:145-151
Ferreira SH, Moncada S, Parsons M, Vane JR (1975) The concomitant release of bradykinin and prostaglandin in the inflammatory response to carrageenan. Br J Pharmacol 52:108-109
Garcia Leme J (1978) Bradykinin system. In: Vane JR, Ferreira SH (eds) Inflammation, Handbuch für experimentelle Pharmakologie, vol. 50/I, Springer, Berlin Heidelberg New York, p.464
Hooper NM, Hryszko J, Oppong SY, Turner AJ (1992) Inhibition by converting enzyme inhibitors of pig kidney aminopeptidase P. Hypertension 19:281-285
Ishida H, Scicli G, Carretero OA (1989a) Role of angiotensin converting enzyme and other peptidases in in vivo metabolism of kinins. Hypertension 14:322-327
Ishida H, Scicli G, Carretero OA (1989b) Contributions of various plasma peptidases to kinin hydrolis. J Pharmacol Exp Ther 251:817-820
Iso T, Yamauchi H, Suda H, Nakajima N, Nishimura K, Iwao J (1978) Potentiative effects of sulfhydryl compounds on carrageenin-induced oedema in rats and relationship to their potencies as inhibitors of angiotensin-converting enzyme in vivo. Experientia 34:1202-1203
Kato H, Enjyoji KI, Miyata T, Hayashi I, Oh-ishi S, Iwanaga S (1985) Demonstration of arginyl-bradykinin moiety in rat HMW kininogen: direct evidence for liberation of bradykinin by rat glandular kallikreins. Biochem Biophys Res Commun 127:289-295
Kato T, Nagatsu T, Fukasawa K, Harada M, Nagatsu I, Sakakibara S (1978) Successive cleavage of N-terminal Arg1-Pro2 and Lys3-Pro4 from substance P but no release of Arg1-Pro2 from bradykinin by X-Pro dipeptidyl-aminopeptidase. Biochem Biophys Acta 525:417-422
Kitamura S, Carbini LA, Carretero OA, Simmons WH, Scicli AG (1995) Potentiation by aminopeptidase P of blood pressure response to bradykinin. Br J Pharmacol 114:6-7
Kumakura S, Kamo I, Tsurufuji S (1988a) Role of bradykinin in the vascular permeability response induced by carrageenin in rats. Br J Pharmacol 93:739-746
Kumakura S, Kamo I, Tsurufuji S (1988b) Nature of kininase activity in the exudate in kaolin-induced inflammation of the air pouch type in rats. Eur J Pharmacol 149:276-275
Maling HM, Webster ME, Williams MA, Saul W, Anderson W (1974) Inflammation induced by histamine, serotonin, bradykinin and compound 48/80 in the rat: antagonists and mechanisms of action. J Pharmacol Exp Ther 191:300-310
Oh-ishi S, Hayashi M, Yamaki K (1986) Inflammatory effects of acetylglycerylether phosphorylcholine: vascular permeability increase and induction of pleurisy in rats. Prostgl Leukotr Med 22: 21-32
Okamoto H, Grenbaum LM (1983) Isolation and structure of T-kinin. Biochem Biophys Res Commun 112:701-708
Orawski AT, Simmons WH (1995) Purification and properties of membrane-bound aminopeptidase P from rat lung. Biochemistry 34:11227-11236
Orawski AT, Susz JP, Simmons WH (1989) Metabolism of bradykinin by multiple coexisting membrane-bound peptidases in lung: techniques for investigating the role of each peptidase using specific inhibitors. Adv Exp Biol Med 247 (Part B):355-364
Pesquero JB, Jubilut GN, Lindsey CJ, Paiva ACM (1992) Bradykinin metabolism pathway in the rat pulmonary circulation. J Hypertension 10:1471-1478
Prechel MM, Orawski AT, Maggiora LL, Simmons WH (1995) Effect of a new aminopeptidase P inhibitor, apstatin, on bradykinin degradation in the rat lung. J Pharmacol Exp Ther 275:1136-1147
Proud D, Kaplan AP (1988) Kinin formation: Mechanisms and role in inflammation disorders. Ann Rev Immunol 6:49-83
Regoli D, Barabé J (1980) Pharmacology of bradykinin and related kinins. Pharacol Rev 32:1-46
Roques BP, Noble F, Daugé V, Fournié-Zaluski MC, Beaumont A (1993) Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 45:87-146
Ryan JW, Chung A, Ryan US (1983) A radioassay for carboxypeptidase N. Adv Exp Med Biol 156 (Part B):867-874
Ryan JW, Berryer P, Chung AAK, Sheffy DH (1994) Characterization of rat pulmonary vascular aminopeptidase P in vivo: role in the inactivation of bradykinin. J Pharmacol Exp Ther 269:941-947
Schillero GJ, Almenoff P, Cardozo C, Lesser M (1994) Effects of peptidase inhibitors on bradykinin-induced bronchoconstriction in the rat. Peptides 15:1445-1449
Skidgel RA (1992) Bradykinin-degrading enzymes: structure, function, distribution, and potential roles in cardiovascular pharmacology. J Cardiov Pharmacol 20 [Suppl. 9]:S4-S9
Sorrentino L, Capasso F (1971) Enhancement of carrageenin foot oedema by 1,10 phenanthroline. Naunyn-Schmiedeberg's Arch Pharmacol 269:482-483
Ura N, Shimamoto K, Nomura N, Aoyama T, Iwata M, Takagawa Y, Iimura O (1995) The mechanism of the renal effects of neutral endopeptidase inhibitor in rats. Clin Exp Hypertension 17:1183-1196
Van Arman CG, Nuss GW (1969) Plasma bradykininogen levels in adjuvant arthritis and carrageenan inflammation. J Pathol 99:245-250
Wang L, Ahmad S, Benter IF, Chow A, Mizutani S, Ward P (1991) Differential processing of substance P and Neurokinin A by plasma dipeptidyl(amino)peptidase IV, aminopeptidase M and angiotensin converting enzyme. Peptides 12:1357-1364
Whalley ET (1987) Receptors mediating the increase in vascular permeability to kinins: comparative studies in rat, guinea-pig and rabbit. Naunyn-Schmiedeberg's Arch Pharmacol 336:99-104
Whalley ET, Sampaio CAM, Fritz, H, Edwards G (1984) The effects of kinins on paw oedema and uterus in rats. Naunyn-Schmiedeberg's Arch Pharmacol 328:202-206
Yong T, Gao XP, Koizumi S, Conlon JM, Rennard SI, Mayhan WG, Rubinstein I (1992) Role of peptidases in bradykinin-induced increase in vascular permeability in vivo. Circ Res 70:952-959
